BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 11298075)

  • 1. Frequency of cytochrome P450 2C9 mutant alleles in a Korean population.
    Yoon YR; Shon JH; Kim MK; Lim YC; Lee HR; Park JY; Cha IJ; Shin JG
    Br J Clin Pharmacol; 2001 Mar; 51(3):277-80. PubMed ID: 11298075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations.
    Gaedigk A; Casley WL; Tyndale RF; Sellers EM; Jurima-Romet M; Leeder JS
    Can J Physiol Pharmacol; 2001 Oct; 79(10):841-7. PubMed ID: 11697742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic polymorphism of cytochrome P450 2C9 in a Caucasian and a black African population.
    Scordo MG; Aklillu E; Yasar U; Dahl ML; Spina E; Ingelman-Sundberg M
    Br J Clin Pharmacol; 2001 Oct; 52(4):447-50. PubMed ID: 11678789
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High frequency of mutations related to impaired CYP2C9 metabolism in a Caucasian population.
    García-Martín E; Martínez C; Ladero JM; Gamito FJ; Agúndez JA
    Eur J Clin Pharmacol; 2001 Apr; 57(1):47-9. PubMed ID: 11372590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population.
    Yasar U; Eliasson E; Dahl ML; Johansson I; Ingelman-Sundberg M; Sjöqvist F
    Biochem Biophys Res Commun; 1999 Jan; 254(3):628-31. PubMed ID: 9920790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency of cytochrome P450 CYP2C9 variants in a Turkish population and functional relevance for phenytoin.
    Aynacioglu AS; Brockmöller J; Bauer S; Sachse C; Güzelbey P; Ongen Z; Nacak M; Roots I
    Br J Clin Pharmacol; 1999 Sep; 48(3):409-15. PubMed ID: 10510154
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism.
    Sullivan-Klose TH; Ghanayem BI; Bell DA; Zhang ZY; Kaminsky LS; Shenfield GM; Miners JO; Birkett DJ; Goldstein JA
    Pharmacogenetics; 1996 Aug; 6(4):341-9. PubMed ID: 8873220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P4502C9 in the oxidation of tolbutamide and warfarin by human liver microsomes.
    Yamazaki H; Inoue K; Shimada T
    Xenobiotica; 1998 Feb; 28(2):103-15. PubMed ID: 9522436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics of warfarin elimination and its clinical implications.
    Takahashi H; Echizen H
    Clin Pharmacokinet; 2001; 40(8):587-603. PubMed ID: 11523725
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between CYP2C9 and 2C19 genotypes and tolbutamide methyl hydroxylation and S-mephenytoin 4'-hydroxylation activities in livers of Japanese and Caucasian populations.
    Inoue K; Yamazaki H; Imiya K; Akasaka S; Guengerich FP; Shimada T
    Pharmacogenetics; 1997 Apr; 7(2):103-13. PubMed ID: 9170147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a null allele of CYP2C9 in an African-American exhibiting toxicity to phenytoin.
    Kidd RS; Curry TB; Gallagher S; Edeki T; Blaisdell J; Goldstein JA
    Pharmacogenetics; 2001 Dec; 11(9):803-8. PubMed ID: 11740344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytochrome P450 2C9 polymorphisms: a comprehensive review of the in-vitro and human data.
    Lee CR; Goldstein JA; Pieper JA
    Pharmacogenetics; 2002 Apr; 12(3):251-63. PubMed ID: 11927841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lung cancer risk in relation to the CYP2C9*1/CYP2C9*2 genetic polymorphism among African-Americans and Caucasians in Los Angeles County, California.
    London SJ; Daly AK; Leathart JB; Navidi WC; Idle JR
    Pharmacogenetics; 1996 Dec; 6(6):527-33. PubMed ID: 9014202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population.
    Hamdy SI; Hiratsuka M; Narahara K; El-Enany M; Moursi N; Ahmed MS; Mizugaki M
    Br J Clin Pharmacol; 2002 Jun; 53(6):596-603. PubMed ID: 12047484
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population.
    Kimura M; Ieiri I; Mamiya K; Urae A; Higuchi S
    Ther Drug Monit; 1998 Jun; 20(3):243-7. PubMed ID: 9631918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients.
    Leung AY; Chow HC; Kwong YL; Lie AK; Fung AT; Chow WH; Yip AS; Liang R
    Blood; 2001 Oct; 98(8):2584-7. PubMed ID: 11588061
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Allele and genotype frequencies of CYP2C9 within an Iranian population (Mazandaran).
    Hashemi-Soteh SM; Shahabi-Majd N; Gholizadeh AR; Shiran MR
    Genet Test Mol Biomarkers; 2012 Jul; 16(7):817-21. PubMed ID: 22288731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphism of the cytochrome P450 (CYP) 2C9 gene in Japanese epileptic patients: genetic analysis of the CYP2C9 locus.
    Imai J; Ieiri I; Mamiya K; Miyahara S; Furuumi H; Nanba E; Yamane M; Fukumaki Y; Ninomiya H; Tashiro N; Otsubo K; Higuchi S
    Pharmacogenetics; 2000 Feb; 10(1):85-9. PubMed ID: 10739176
    [No Abstract]   [Full Text] [Related]  

  • 19. Influence of cytochrome P450 CYP2C9 genotypes in lung cancer risk.
    García-Martín E; Martínez C; Ladero JM; Gamito FJ; Rodriguez-Lescure A; Agúndez JA
    Cancer Lett; 2002 Jun; 180(1):41-6. PubMed ID: 11911968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis.
    Aithal GP; Day CP; Leathart JB; Daly AK
    Pharmacogenetics; 2000 Aug; 10(6):511-8. PubMed ID: 10975605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.